Article Text
Abstract
In the USA, there are missed opportunities to diagnose hepatitis C virus (HCV) in pregnancy because screening is currently risk-stratified and thus primarily limited to individuals who disclose history of injection drug use or sexually transmitted infection risks. Over the past decade, the opioid epidemic has dramatically increased incidence of HCV and a feasible, well-tolerated cure was introduced. Considering these developments, recent evidence suggests universal HCV screening in pregnancy would be cost-effective and several professional organisations have called for updated national policy. Historically, universal screening has been financially disincentivised on the healthcare system level, particularly since new diagnoses may generate an obligation to provide expensive treatments to a population largely reliant on public health resources. Here, we provide ethical arguments supporting universal HCV screening in pregnancy grounded in obligations to respect for persons, beneficence and justice. First, universal prenatal HCV screening respects pregnant women as persons by promoting their long-term health outside of pregnancy. Additionally, universal screening would optimise health outcomes within current treatment guidelines and may support research on treatment during pregnancy. Finally, universal screening would avoid potential harms of risk-stratifying pregnant women by highly stigmatised substance use and sexual behaviours.
- health care economics: interests of woman/fetus/father
- ostetrics and gynecology
- public health ethics: drugs and drug industry
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Read the full text or download the PDF:
Other content recommended for you
- Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy
- Changes in hepatitis C burden and treatment trends in Europe during the era of direct - acting antivirals: a modelling study
- Improving hepatitis C screening and diagnosis in patients born between 1945 and 1965 in a safety - net primary care clinic
- Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study
- Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness - implementation trial evaluating an integrated model of HCV care (DRIVE - C: DRug use & Infections in ViEtnam – hepatitis C)
- Retrospective hepatitis C seroprevalence screening in the antenatal setting — should we be screening antenatal women
- On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017
- Trends in hepatitis C treatment initiation among HIV / hepatitis C virus - coinfected men engaged in primary care in a multisite community health centre in Maryland: a retrospective cohort study
- Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis
- Screening, diagnosis and care cascade for viral hepatitis B and C in Yaoundé, Cameroon: a qualitative study of patients and health providers coping with uncertainty and unbearable costs